Future strategies targeting vitamin D signaling in muscle and modulating the VDR “metabolome” may also hold important clues for future treatments of musculoskeletal disorders, congenital myopathies, and sarcopenia. This evidence concerns the gene VDR and congenital myopathy with cores.